Welcome to Apotex

Public Advisory
January 2005 - Important safety information for patients taking Apo-Mefloquine (mefloquine) for the prevention of malaria

January 25, 2006
Apotex Receives Approval for First Generic Plavix®
WESTON, FLORIDA, U.S.A. – Apotex Corp. today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clopidogrel bisulfate 75 mg tablets...

March 14, 2005
Canadian Facility Chosen As One The 5 Finalists For The 2005 Global Award for the "Pharmaceutical Facility of The Year"
TORONTO, ONTARIO, CANADA – The Apotex Inc. Etobicoke Pharmaceutical Expansion Project has been chosen as one of 5 finalists for the 2005 Global Award for “Facility Of The Year” by ISPE...

February 21, 2005
$3 Million Gift to Help Establish Cutting Edge Facility for Faculty of Pharmacy
WINNIPEG, MANITOBA, CANADA – Apotex Inc. has pledged $3 million to assist the Faculty of Pharmacy create a new teaching and research facility on the University of Manitoba's Bannatyne campus...

January 5, 2005
Canadian Pharma Company Sets Bar For Company Donating For Tsunami Relief Efforts
TORONTO, ONTARIO, CANADA – Apotex Inc., the largest Canadian-owned pharmaceutical company is assisting in the Tsunami Relief efforts in two clear ways....

Public Advisory January 2005 - Important safety information for patients taking Apo-Mefloquine (mefloquine) for the prevention of malaria

Public Advisory
January 2005 - Important safety information for patients taking Apo-Mefloquine (mefloquine) for the prevention of malaria